DIANTHUS THERAPEUTICS INC (DNTH) — insider trading
Health Care · NASDAQ
DIANTHUS THERAPEUTICS INC (DNTH) has 33 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 33 (latest 2026-07-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion (derivative) | 31,249 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 5,566 | $101.97 | $567.6K | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 15,329 | $101.24 | $1.55M | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 10,354 | $100.22 | $1.04M | Form 4 |
| 2026-07-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion | 31,249 | $21.77 | $680.3K | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 13,229 | $81.38 | $1.08M | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Open-market sale | 16,771 | $80.34 | $1.35M | Form 4 |
| 2026-06-17 | Veness Adam M | Officer (SVP, General Counsel and Sec.) | Option exercise / conversion | 30,000 | $17.88 | $536.4K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 9,375 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 6,249 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 6,908 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 3,998 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 4,159 | $91.37 | $380.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 16,943 | $90.72 | $1.54M | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Open-market sale | 5,428 | $89.72 | $487.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 9,375 | $22.07 | $206.9K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 6,249 | $21.77 | $136.0K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 6,908 | $17.88 | $123.5K | Form 4 |
| 2026-06-01 | Randhawa Simrat | Officer (EVP, Head of R&D) | Option exercise / conversion | 3,998 | $8.44 | $33.7K | Form 4 |
| 2026-05-21 | Soteropoulos Paula | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Violin Jonathan | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | KANGO SUJAY | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Lawton Alison Frances | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | McGeorge Anne | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Romano Steven J. | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Read Simon | Director | Grant / award / vesting (derivative) | 6,090 | $0.00 | $0 | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Option exercise / conversion (derivative) | 599 | $0.00 | $0 | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Open-market sale | 599 | $85.47 | $51.2K | Form 4 |
| 2026-05-08 | Soteropoulos Paula | Director | Option exercise / conversion | 599 | $8.44 | $5.1K | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion (derivative) | 8,224 | $0.00 | $0 | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Open-market sale | 8,224 | $89.84 | $738.8K | Form 4 |
| 2026-04-09 | Savitz Ryan | Officer (EVP, CFO & CBO) | Option exercise / conversion | 8,224 | $17.88 | $147.0K | Form 4 |
Ask the chat about DNTH's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DIANTHUS THERAPEUTICS INC (DNTH).
Last updated 2026-07-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.